Bottom line
FBTAX vs BIB: the short answer
FBTAX (Fidelity Advisor Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 26% of their top holdings (by weight) are shared.
But BIB is far broader, holding 267 positions to 129 for FBTAX, so beyond the top names it adds exposure FBTAX doesn't have.
FBTAX is cheaper at 0.94% vs 0.95% — a difference of $1.00 a year per $10,000 invested.
Over five years, FBTAX returned +6.4% a year vs −1.0% for BIB (reporting dates differ).
Updated Nov 19, 2026
FBTAX vs BIB side by side
| FBTAX | BIB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Fidelity | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.94% | 0.95% |
| Annual cost per $10k | $94 | $95 |
| 10-yr cost on $10k (prospectus) | $1,663 | $1,401 |
| Max front load | — | None |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +31.5% | +59.3% |
| 5-yr return (annualized) | +6.4% | −1.0% |
| 10-yr return (annualized) | +7.7% | +1.4% |
| Best quarter | +30.3% | +56.2% |
| Worst quarter | −27.8% | −42.7% |
| Net assets (fund) | $2.2B | $73.7M |
| Number of holdings | 129 | 267 |
| Portfolio turnover | 54% | 29% |
| Returns as of | Sep 30, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FBTAX | BIB | Difference |
|---|---|---|---|
| 2025 | +39.6% | +59.3% | −19.8% |
| 2024 | +5.3% | −10.0% | +15.3% |
| 2023 | +10.7% | −1.3% | +12.0% |
| 2022 | −8.0% | −28.6% | +20.7% |
| 2021 | −3.6% | −5.9% | +2.4% |
| 2020 | +32.2% | +39.7% | −7.6% |
| 2019 | +25.7% | +45.5% | −19.8% |
| 2018 | −3.8% | −24.4% | +20.6% |
| 2017 | +25.8% | +40.8% | −15.0% |
| 2016 | −23.6% | −44.2% | +20.7% |
Source: Fund prospectus bar charts
Holdings overlap
9 of FBTAX's top 25 holdings also appear in BIB's top 25.
| Holding | FBTAX | BIB |
|---|---|---|
| Gilead Sciences Inc | 5.70% | 4.66% |
| Alnylam Pharmaceuticals Inc | 3.62% | 2.01% |
| Insmed Inc | 3.05% | 1.16% |
| Revolution Medicines Inc | 3.00% | 1.57% |
| Argenx Se | 3.00% | 1.19% |
| Biogen Inc | 2.71% | 1.44% |
| Amgen Inc | 2.37% | 4.48% |
| Moderna Inc | 1.60% | 0.94% |
| Vertex Pharmaceuticals Inc | 1.39% | 4.65% |
Source: SEC Form N-PORT
FBTAX top 10
- Abbvie Inc — 14.71%
- Gilead Sciences Inc — 5.70%
- Spyre Therapeutics Inc — 3.83%
- Alnylam Pharmaceuticals Inc — 3.62%
- Dianthus Therapeutics Inc — 3.55%
- Cogent Biosciences Inc — 3.25%
- Oruka Therapeutics Inc — 3.24%
- Insmed Inc — 3.05%
- Revolution Medicines Inc — 3.00%
- Argenx Se — 3.00%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between FBTAX and BIB?
Which is cheaper, FBTAX or BIB?
Should I own both FBTAX and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.